Eupraxia Pharmaceuticals's total assets for Q2 2025 were C$23.60M, a decrease of -19.28% from the previous quarter. EPRX total liabilities were C$2.62M for the fiscal quarter, a 19.02% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.